Anti-depression traditional Chinese medicine composition and application
By limiting the ratio of Chaihu saponin, Paeoniae, Atractylodes lactide III and Mangnae, antidepressant Chinese medicine compositions were prepared to regulate core target proteins and signaling pathways, and the problem of instability of drug dosage caused by the complexity of Xiaoyao Pills was solved. , achieving precise control of anti-depressive effects and excellent therapeutic effects.
Patent Information
- Application Number
- CN202411171625.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-03
AI Technical Summary
Xiaoyao Pills have complex chemical compositions, and the content of active ingredients is difficult to accurately control, which affects the stability of the drug dose and leads to inconsistent anti-depressive effects.
By defining the mass ratio of bupleurin, peony root, atractylodes lactide III and marsin, an antidepressant Chinese medicine composition is prepared to regulate core target proteins and signaling pathways, and to regulate oxidative stress and inflammatory responses.
The precise control of the dosage was achieved, which significantly reduced the inflammatory mediators and factors in the blood and hippocampal tissues of CUMS model rats, and the effect was better than that of Western medicine and classic prescription Xiaoyao Pills.
Smart Images

Figure CN119055665A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to an antidepressant traditional Chinese medicine composition and application. Background Art
[0002] Xiaoyao Pills originated from Xiaoyao Powder in the Song Dynasty's Taiping Huimin Hejijufang. It is composed of eight herbs, including Bupleurum, Angelica, and White Peony. It is one of the classic prescriptions for treating liver depression and spleen deficiency. It has the effects of soothing the liver and relieving depression, nourishing blood and nourishing the body. It is often used in clinical practice to treat liver diseases, gynecological diseases, and central nervous system disorders caused by liver depression. Modern pharmacological studies have shown that Xiaoyao Pills have a good antidepressant effect, and its mechanism of action may be related to regulating the levels of monoamine neurotransmitters and cytokines in serum.
[0003] The chemical composition and antidepressant mechanism of Xiaoyao Pills are complex, and Chinese medicine contains many ingredients. The content of active ingredients will be affected by the origin or age of the medicine, and the dosage cannot be accurately controlled. It is necessary to study the active ingredients of Xiaoyao Pills and obtain a combination of active ingredients that can be purchased or directly extracted, and achieve similar effects to Xiaoyao Pills to realize precise control of the dosage. Summary of the invention
[0004] In view of this, the purpose of the present invention is to provide an antidepressant Chinese medicine composition and application. By limiting the composition of the active ingredients of the medicine, the dosage can be precisely controlled to avoid being affected by the medicinal materials themselves.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides an antidepressant traditional Chinese medicine composition, comprising the following components in parts by weight:
[0007] 1.0-4.0 parts of saikosaponin D, 1.0-5.0 parts of paeoniflorin, 0.5-2.0 parts of atractylodes lactone III, and 0.5-2.0 parts of formononetin.
[0008] Preferably, the following components are included in parts by weight:
[0009] 1.5-3.0 parts of saikosaponin D, 2.0-4.0 parts of paeoniflorin, 0.7-1.5 parts of atractylodes lactone III, and 0.7-1.5 parts of formononetin.
[0010] Preferably, the following components are included in parts by weight:
[0011] 2.0 parts of saikosaponin D, 3.0 parts of paeoniflorin, 1.0 part of atractylodes lactone III, and 1.0 part of formononetin.
[0012] The present invention also provides application of the composition in preparing antidepressant drugs.
[0013] Preferably, the core target proteins acted upon by the composition include PTGS2, PPARG, SRC, MMP9, and ESR1.
[0014] Preferably, the method by which the composition regulates core target proteins and signaling pathways and metabolic pathways includes regulating oxidative stress and inflammatory responses.
[0015] Compared with the prior art, the present invention has the following beneficial effects:
[0016] The four active ingredients in the composition of the present invention are easy to obtain, can be extracted from traditional Chinese medicine, or can be commercially synthesized. The antidepressant composition of the present invention has a clear material basis for efficacy, a clear structure, fixed components and controllable quality. The composition can play a synergistic and enhanced protective effect on glutamate-induced PC12 cell damage, has a synergistic and enhanced inhibitory effect on the release of lactate dehydrogenase (LDH), and can significantly reduce the content of iNOS, NO, COX-2, PGE2, TNF-α, IL-1β, IL-18, IL-6 and IFN-γ in the blood and hippocampal tissue of CUMS model rats. The effect is better than that of the positive control group of western medicine and the effect of single use, and is equivalent to the effect of the classic prescription Xiaoyao Pills. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 These are the components of Xiaoyao Pills extract that enter the blood and brain in vivo, where A is the LC-MS total ion current of rat blank serum, B is the LC-MS total ion current of rat drug-containing serum, C is the extracted ion current of 6 blood-entering components, and D is the extracted ion current of the brain-entering components in rat brain tissue; 1 is adenosine, 2 is menthone, 3 is paeoniflorin, 4 is formononetin, 5 is bupleurosaponin d, and 6 is atractylodes lactone III.
[0018] Figure 2 Network diagram of active ingredients screened for metabolomics association of active ingredients.
[0019] Figure 3 Schematic diagram of docking of effective components with potential core target molecules, where A is atractylodes lactone III-GSK3B, B is atractylodes lactone II-ESR1, C is peonyside I-ESR1, D is formononetin-GSK3B, E is saikosaponin d-PTGS2, and F is saikosaponin d-PPARG.
[0020] Figure 4 The present invention shows the effects of the Chinese medicine composition and monomer on the survival rate of PC12 cells induced by glutamate, wherein A is the Chinese medicine composition; B is paeoniflorin; C is formononetin; D is atractylodes lactone III; and E is saikosaponin d.
[0021] Figure 5The Calcein / PI fluorescence staining diagram of the Chinese medicine composition of the present invention after glutamate injury, wherein the left diagram is the fluorescence staining diagram, and the right diagram is the fluorescence expression quantitative diagram.
[0022] Figure 6 These are fluorescence staining diagrams of the effect of the Chinese medicine composition of the present invention on the level of intracellular ROS, wherein the left diagram is a fluorescence staining diagram, and the right diagram is a fluorescence expression quantitative diagram.
[0023] Figure 7 This is a graph showing the effect of the Chinese medicine composition of the present invention on the activity of intracellular antioxidant enzymes. DETAILED DESCRIPTION
[0024] The present invention provides an antidepressant traditional Chinese medicine composition, comprising the following components in parts by weight:
[0025] 1.0 to 4.0 parts of saikosaponin D, preferably 1.5 to 3.0 parts, more preferably 2.0 parts;
[0026] 1.0 to 5.0 parts of paeoniflorin, preferably 2.0 to 4.0 parts, more preferably 3.0 parts;
[0027] 0.5 to 2.0 parts of Atractylodes lactone III, preferably 0.7 to 1.5 parts, more preferably 1.0 parts;
[0028] The amount of formononetin is 0.5 to 2.0 parts, preferably 0.7 to 1.5 parts, and more preferably 1.0 part.
[0029] In the present invention, the purity of the components is preferably ≥90%, more preferably ≥95%, and even more preferably ≥98%.
[0030] The present invention also provides application of the composition in preparing antidepressant drugs.
[0031] In the present invention, the core target proteins acted upon by the composition include PTGS2, PPARG, SRC, MMP9, and ESR1.
[0032] In the present invention, the method for the composition to regulate core target proteins and signaling pathways and metabolic pathways includes regulating oxidative stress and inflammatory response.
[0033] The CCK8 kit was purchased from Beijing Bioson Biotechnology Co., Ltd.;
[0034] LDH kit, SOD kit, GSH kit, and MDA kit were purchased from Nanjing Jiancheng Bioengineering Institute;
[0035] DCFH-DA fluorescent probe was purchased from MCE, USA;
[0036] DAPI and live / dead cell double staining kit were purchased from Beijing Solarbio Company;
[0037] Bax / bcl-2 and anti-rabbit IgG were purchased from Proteintech;
[0038] Bcl-2 antibody and Bax antibody were purchased from Wuhan Tri-Tek Co., Ltd.;
[0039] The fixative and Fluo-4 AM (calcium ion fluorescent probe) were purchased from Shanghai Bio-Tech Biotechnology Co., Ltd.
[0040] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0041] Embodiment 1 The compatibility of effective components
[0042] In view of the complexity of Chinese medicine components, the contribution rate of each component in Chinese medicine components to exert the efficacy is different. According to the content of the 7 effective components in Xiaoyao Pills, the 7 effective components were designed with their mass ratio as the weight to determine the optimal compatibility ratio. In order to investigate the synergistic compatibility between the effects, the principle of "1+2+3" was adopted. The soothing liver group, the strengthening spleen group, and the nourishing blood group were divided into 3 groups (combinations 1, 2, and 3) separately, and the effects were divided into 3 groups (combinations 4, 5, and 6) in pairs, and the effects were divided into 4 groups (combinations 7, 8, 9, and 10) in combination. The specific information is shown in Table 1.
[0043] Table 1 Effective group distribution ratio table
[0044]
[0045] Example 2 Activity evaluation of effective ingredients of traditional Chinese medicine and screening of optimal ratio
[0046] 1. Evaluation of the activity of the active ingredient combination on glutamate-induced PC12 cell damage
[0047] (1) Cell culture: PC12 cells were purchased from Prosai Co., Ltd. and cultured at 37°C with 5% CO 2 Culture the cells in an incubator and replace the culture medium every 1-2 days, or when the culture medium turns yellow. Subculture the cells every 3-5 days when the cells are about to cover the bottom of the culture flask.
[0048] (2) Plating: When cells have grown into a monolayer, add 0.25% trypsin to digest for 1 min, terminate digestion with serum-containing 1640 medium, and adjust the cell concentration to 10,000 cells / well. Inoculate the cells in a 96-well culture plate with 100 μL per well and place in a CO 2Incubator culture. Set up blank control group, normal control group, model control group, positive control group, and 10 combination groups, and set up 6 replicates in each group.
[0049] (3) Administration: After 24 hours of culture, 100 μl of normal culture medium (RMPI 1640 culture medium containing 10% serum) was added to the blank control group, 100 μl of 12.5 mmol / L glutamate solution was added to the model group, and 10 mmol / L fluoxetine solution was added to the positive control group. The composition in the administration group was a mixture of several components, and the proportions were prepared according to Table 1. Each administration group was added with a concentration of 10 -6 The 10 prepared combination solutions of 1:1 mol / L were placed in the incubator and cultured for 24 hours.
[0050] (4) Cell viability detection: After 24 h of culture, the culture medium was discarded, 10 μL of CCK-8 solution was added to each well, and the cells were incubated for another 1 h. The absorbance at 450 nm was measured using a microplate reader. The OD value was used for calculation: cell viability % = OD value of the treatment group / OD value of the blank control group × 100%.
[0051] (5) Lactate dehydrogenase (LDH) activity detection: After the culture, take 100 μL of the supernatant and place it in a new 96-well plate. According to the instructions of the LDH assay kit, mix well, leave it at room temperature for 5 minutes, and measure the absorbance value with a microplate reader at a wavelength of 450 nm. LDH activity (U / L) = [(A assay - A control) / (A standard - A blank)] × C standard × N × 100%.
[0052] 2. Entropy weight method to select the best combination
[0053] Based on the comprehensive score of cell survival rate and lactate dehydrogenase (LDH) release rate, the entropy weight method was used to calculate the original evaluation index matrix (X ij )mn, normalize the data and build the probability matrix P ij ; Secondly, calculate the information entropy of each indicator (E ij ) and weight coefficient (Wj), and then calculate the comprehensive score (W) based on Wj.
[0054] ① Establish the original evaluation index matrix (X ij ):
[0055] Survival rate (positive indicator): X ij =(X j -X min ) / (X max -X min )
[0056] LDH release rate (negative indicator): X ij =(X max-X j ) / (X max -X min )
[0057] Where X j is the jth index value, X max is the maximum value of the jth index, X min is the minimum value of the j-th indicator.
[0058] ② Calculate the probability matrix (P ij ):
[0059]
[0060] ③Calculate the information entropy of the indicator (E ij ):
[0061]
[0062] Among them, constant k>0, k=1 / ln m, ensuring 0≤E j ≤1, that is, E j Maximum is 1
[0063] The entropy value of the jth indicator is:
[0064]
[0065] ④ Calculate the weight coefficient of each indicator (W j ):
[0066]
[0067] The results are shown in Table 2.
[0068] Table 2 Experimental results of 10 combinations designed by splitting method and entropy weight method
[0069]
[0070] ** P<0.01, compared with the normal group; # P<0.05, ## P<0.01, compared with the model group
[0071] According to Table 2, the W entropies of the 10 combinations calculated in the above steps are 0.5209, 0.3557, 0.3276, 0.4164, 0.4681, 0.6096, 0.6631, 0.3501, 0.3204, and 0.0961, respectively. It can be seen that combination ⑦ is the best combination.
[0072] As shown in Table 2, compared with the survival rate of the normal group, the cell survival rate of the model group was significantly decreased (P<0.01), and the LDH release rate was significantly increased, indicating that the model was successful. Compared with the model group and the combination ①-combination ⑩ groups, after the intervention of combination ①-combination ⑩, the cell damage effect was improved, thereby increasing the cell survival rate (P<0.01), especially the combination ⑦. Compared with the model group, combination ①-combination ②, combination ④-combination ⑦, and combination ⑩ significantly reduced the LDH release rate (P<0.01), and combination ③, combination ⑧-combination ⑨ had a significant change in the cell LDH release rate. On this basis, the survival rate and LDH release rate were taken as the investigation factors, and the entropy weight method was used to determine the weight coefficient of each group. The best effective component was screened out by the weight coefficient score. The results are shown in Table 2. The comprehensive score of each combination was calculated according to the entropy weight method. The larger the weight coefficient, the higher the importance of the indicator in the evaluation and the greater the impact on the evaluation result. The results showed that combination ⑦ had the highest comprehensive score among all combinations, and its specific ratio combination had the best protective effect on glutamate-induced PC12 cell damage. The optimal ratio was 2.0:3.0:1.0:1.0 for the group of soothing the liver + strengthening the spleen + nourishing the blood: saikosaponin d: paeoniflorin: atractylodes lactone III: formononetin.
[0073] Example 3 Pharmacodynamic Verification of the Optimal Ratio Composition of Active Ingredients of Traditional Chinese Medicine (Cell Experiment)
[0074] Cell culture, modeling, drug administration, and grouping were the same as in Example 2.
[0075] Calcein / PI staining: After drug treatment, PC12 cells were stained with Calcein-AM and PI according to the instructions of the Solebol kit. After staining, the cells were photographed under a fluorescence confocal microscope and the fluorescence intensity was calculated.
[0076] Experimental results: The optimal ratio group was observed under a confocal microscope at a concentration of 10 -6 mol / L after the cell survival and apoptosis, such as Figure 4 As shown, green represents living cells and red represents dead cells. Compared with the normal control group, the cells in the model group showed obvious cell shrinkage, a significant decrease in living cells, and a significant increase in dead cells. After drug treatment, the optimal ratio group can reduce the number of dead cells and maintain normal cell morphology.
[0077] Reactive oxygen species (ROS) detection: After the culture, the cells were labeled with DCFH-DA probe for 20 min, and then the excess probe was washed away with culture medium. Hoechst reagent was added for staining for 15 min, and finally confocal microscopy was used for detection.
[0078] Experimental results: The optimal ratio group was observed under a confocal microscope at a concentration of 10 -6mol / L after the action of the active oxygen in the cells, such as Figure 5 As shown, the production of ROS in cells of the model group increased significantly, and administration of the optimal ratio group could significantly reduce the production of ROS in cells. The results confirmed that the optimal ratio group could reduce the damage of oxidative stress to cells.
[0079] Total superoxide dismutase (SOD), reduced glutathione (GSH) and malondialdehyde (MDA) activity detection: After the culture was completed, cell lysis solution was added and the cells were lysed on ice for 30 min. After lysis, the cells were centrifuged at 4°C, 3000 rpm for 5 min, the supernatant was collected, and the protein concentration was determined using a BCA protein detection kit. Then, according to the instructions of the kit, the OD value was determined using a microplate reader, and the SOD, GSH and MDA activities of each group were calculated.
[0080] Experimental results: The optimal ratio group has an effect on the activities of SOD, GSH and MDA in PC12 cells induced by glutamate. Figure 6 As shown in the figure, compared with the blank control group, the activities of intracellular antioxidant substances SOD and GSH in the model group were significantly reduced, and the level of lipid peroxidation product MDA was significantly increased; compared with the model group, the optimal ratio group could significantly increase the levels of endogenous antioxidant substances SOD and GSH in PC12 cells, and significantly reduce the level of lipid peroxidation product MDA. In summary, the optimal ratio group is the soothing liver + strengthening spleen + nourishing blood group, and the ratio of its components saikosaponin d: paeoniflorin: atractylodes lactone III: formononetin is 2.0:3.0:1.0:1.0, indicating that the 7 active ingredients can synergistically play a neuroprotective role by significantly reducing glutamate-induced PC12 cell apoptosis, intracellular LDH release and cell ROS production.
[0081] Example 4 Pharmacodynamic Verification of the Optimal Ratio Composition of Chinese Medicine Active Ingredients (Animal Experiment)
[0082] 1. Experimental Materials
[0083] 1.1 Animals
[0084] Fifty SPF male SD rats, weighing (250 ± 10) g, were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd., with a production license number of SCXK (Xiang) 2019-0004. The experimental animals were kept in the First Affiliated Medical Innovation Experimental Center of Hunan University of Chinese Medicine, and were approved by the Animal Ethics Review of the First Affiliated Hospital of Hunan University of Chinese Medicine, with approval number ZFY202211-5-1.
[0085] 1.2 Preparation of drugs and intragastric administration solution
[0086] (1) Fluoxetine hydrochloride dispersible tablets (Prozac, specification 20 mg) were obtained from Pfizer Pharmaceuticals Co., Ltd. Six dispersible tablets were taken, crushed and dissolved in 200 ml of normal saline to prepare 0.60 mg mL -1 Suspension, oral administration dose is 2.6 mg kg -1 ·d -1 (equivalent to twice the clinical equivalent dose).
[0087] (2) Xiaoyao Pills: from Zhongjing Wanxi Pharmaceutical Co., Ltd. According to the calculation method of equivalent dose coefficients for different animals in the Methodology of Pharmacological Research of Traditional Chinese Medicine, the dosage of Xiaoyao Pills was calculated based on the previous experimental basis, which was twice the clinical effective dose in rats (0.3564 g kg -1 ·d -1 ) After Xiaoyao Pills were ground into fine powder, 42.72 g of powder was accurately weighed into 600 mL of pure water, shaken up and down, and ultrasonicated for 30 min to obtain a crude drug content of 0.0712 g·mL -1 The Xiaoyao Pill suspension was stored in a 4°C refrigerator for later use. Shake well before each intragastric administration. The administration volume was 10 ml kg -1 .
[0088] (3) Composition of effective Chinese medicine ingredients: paeoniflorin, saikosaponin d, atractylodes lactone III, and formononetin were purchased from Chengdu Pufeide Biotechnology Co., Ltd. with a purity of >98.0%. Saikosaponin d, paeoniflorin, atractylodes lactone III, and formononetin were mixed in a ratio of 2.0:3.0:1.0:1.0 and then added with normal saline to prepare a 7.0 mg / ml suspension [the animal dosage of the effective Chinese medicine composition was determined by previous experimental studies and the dosage of paeoniflorin monomer with the largest ratio (Li Yingchun. Study on the effect of paeoniflorin on improving depressive-like behavior of offspring of prenatal stress through HPA axis and GR [D]. Northwest University, 2021.)], and the animal gavage dosage was 30.0 mg kg -1 ·d -1 .
[0089] 2. Methods
[0090] (1) Modeling: The animal model was established using the single cage solitary housing and CUMS model for 28 days, including 8 stress methods, including fasting and water deprivation for 24 hours, moist bedding for 24 hours, 4°C ice water bath for 3 minutes, cage tilting at 45° for 24 hours, noise for 4 hours, tail clamping for 3 minutes, day and night reversal for 24 hours, and restraint for 1 hour. The stress methods for two consecutive days were not repeated and were randomly distributed in the four stress cycles.
[0091] (2) Grouping and administration: After 7 days of adaptive feeding, SD rats were randomly divided into 5 groups, namely normal group (N group), model group (M group), positive control group (fluoxetine), Xiaoyao pill group (XYW group), and Chinese medicine effective component group, with 10 rats in each group. The positive control group was fed with fluoxetine hydrochloride suspension prepared by 1.2 (1), the Xiaoyao pill group was fed with Xiaoyao pill suspension prepared by 1.2 (3), and the Chinese medicine effective component group was fed with suspension prepared by 1.2 (3) for 28 consecutive days. The normal group and model group were given normal saline.
[0092] (3) Behavioral testing
[0093] Open field test: The rats were placed in the central grid of the bottom of the homemade open box. After 30 seconds of adaptation, the activity trajectory of the rats was recorded within 4 minutes. The number of times the rats' hind limbs stood up, the number of times a certain limb crossed the grid, the static time, and the total number of activities were recorded.
[0094] Forced swimming test: The rats were placed in a forced swimming cup, the water level was determined by the tip of the rat's tail not touching the bottom, and the water temperature was maintained at 25±1℃. The immobility state was defined as the rat's limbs were immobile and floating on the water surface. After 30 seconds of adaptation, the immobility time within 4 minutes was recorded.
[0095] Morris water maze experiment: After the model is established, the rats will be trained in the Morris water maze experiment for 5 days. The rats will be placed in the water facing the pool wall from the four water entry points in a counterclockwise direction. The system records the time it takes the rats to find and climb onto the platform as the escape latency. If the platform is not found within 60 seconds, it will be guided to find the platform and stay for 15 seconds. The last day of the experiment is the space exploration period, and the platform is withdrawn.
[0096] (4) Detection of inflammatory mediators and inflammatory factors in serum
[0097] On the day after the last administration, the rats' eyeballs were removed and blood was collected. The blood was centrifuged at 3500 r / min for 10 min, and the supernatant was collected. The levels of inflammatory mediators (iNOS, COX-2, PGE2) and inflammatory factors (TNF-α, IL-1β, IL-18, IL-6, IFN-γ) in serum were detected according to the method described in the ELISA kit instructions.
[0098] (5) Detection of inflammatory mediators and inflammatory factors in hippocampal tissue
[0099] After blood collection, rats were quickly decapitated to remove brains, hippocampal tissues were separated on ice, placed in 1.5 mL cryotubes, and physiological saline was added at a mass volume ratio (W / V) of 1:9. Homogenization was performed on ice to prepare tissue homogenate, which was centrifuged at 4°C and 3000g for 30 min to collect the supernatant. The supernatant was taken and the contents of inflammatory mediators (iNOS, COX-2, PGE2) and inflammatory factors (TNF-α, IL-1β, IL-18, IL-6, IFN-γ) in hippocampal tissues were detected according to the method described in the ELISA kit instructions.
[0100] (6) Statistical processing
[0101] SPSS 25.0 software was used for statistical analysis. T test was used for comparison between two groups, and one-way analysis of variance was used for comparison between multiple groups. Data transformation was performed when variance was unequal, and P < 0.05 indicated that the difference was statistically significant.
[0102] 3. Results
[0103] (1) Effects on the behavior of CUMS model rats. The results are shown in Table 3.
[0104] Table 3 Effects of intervention in each group on the behavior of CUMS model rats ( n=10)
[0105]
[0106] Compared with the CUMS model control group, *P<0.05, **P<0.01 (the same below).
[0107] The behavioral effects results in Table 3 showed that compared with the normal group, the immobility time of the rats in the CUMS model group in the forced swimming test was significantly increased (P<0.01), the number of rats climbing the grid in the open field test was significantly reduced (P<0.01), and the number of rats crossing the platform in the water maze test was significantly reduced (P<0.01), indicating that the model was successful; compared with the CUMS model group, the weight of the rats in the positive control group, Xiaoyao pill group and Chinese medicine effective ingredient group increased after modeling and medication, the immobility time of the rats in the forced swimming test was significantly reduced (P<0.01), the number of rats climbing the grid in the open field test was significantly increased (P<0.01), and the number of rats crossing the platform in the water maze test was significantly increased (P<0.01), as shown in Table 3. Figure 3 AD), indicating that the Chinese medicine composition can significantly improve the depressive-like behavior of rats, which is comparable to the effect of Xiaoyao Pills.
[0108] (2) Effects on the levels of inflammatory mediators and inflammatory factors in the blood and hippocampal tissue of CUMS model rats. The results are shown in Tables 4 and 5.
[0109] Table 4 Effects of intervention in each group on the levels of inflammatory mediators and inflammatory factors in the blood of CUMS model rats ( n=10)
[0110]
[0111] Table 5 Effects of each group of intervention on the contents of inflammatory mediators and inflammatory factors in the hippocampus of CUMS model rats ( n=10)
[0112]
[0113]
[0114] Compared with the normal control group, the levels of inflammatory mediators (iNOS, NO, COX-2, PGE2) and inflammatory factors (TNF-α, IL-1β, IL-18, IL-6, IFN-γ) in the blood and hippocampus of CUMS model rats were significantly increased (P<0.01); compared with the CUMS model control group, the levels of inflammatory mediators (iNOS, NO, COX-2, PGE2) and inflammatory factors (TNF-α, IL-1β, IL-18, IL-6, IFN-γ) in the blood and hippocampus of the positive control group, Xiaoyao pill group and Chinese medicine effective component group were significantly reduced (P<0.05 or P<0.01). It suggests that the Chinese medicine composition can significantly improve the depressive-like behavior of rats, which is equivalent to the effect of Xiaoyao pill.
[0115] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. An antidepressant Chinese medicine composition, It is characterized in that The composition includes the following components in parts by weight: 1.0-4.0 parts of saikosaponin D, 1.0-5.0 parts of paeoniflorin, 0.5-2.0 parts of atractylodes lactone III, and 0.5-2.0 parts of formononetin.
2. The composition according to claim 1, It is characterized in that The composition includes the following components in parts by weight: 1.5-3.0 parts of saikosaponin D, 2.0-4.0 parts of paeoniflorin, 0.7-1.5 parts of atractylodes lactone III, and 0.7-1.5 parts of formononetin.
3. The composition according to claim 1, It is characterized in that The composition includes the following components in parts by weight: 2.0 parts of saikosaponin D, 3.0 parts of paeoniflorin, 1.0 parts of atractylodes lactone III, and 1.0 parts of formononetin.
4. Use of the composition according to any one of claims 1 to 3 in the preparation of antidepressant drugs.
5. The use according to claim 4, It is characterized in that The core target proteins acted by the composition include PTGS2, PPARG, SRC, MMP9, and ESR1.
6. The use according to claim 5, It is characterized in that The method by which the composition regulates core target proteins and signaling pathways and metabolic pathways includes regulating oxidative stress and inflammatory responses.
Citation Information
Patent Citations
Composition with effect of synergistically resisting depression and application
CN110169974A
